ÈËÆÞÖгöÊÓƵ

Kevin B. Jones
( out of 124 reviews )

Kevin B. Jones, MD

Languages spoken: English, Spanish

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Sarcoma
Salt Lake City
801-585-7180

Primary Children's Hospital

Pediatric Orthopaedics
Salt Lake City
801-662-5600

  • Kevin B. Jones, MD

    Leader, Huntsman Cancer Institute Sarcoma Disease Center

    Division Chief, Sarcoma, Department of Orthopaedics

    Professor, Department of Orthopaedics and

    Adjunct Professor of Oncological Sciences

    As an orthopaedic surgeon specialized in the care of pediatric and adult patients with sarcoma, I see first-hand the limitations and frank failures of the currently available treatment options. Not only do we fail to cure far too many young patients with sarcomas, but the long-term effects of our treatments create other major challenges to the health of the survivors in the long term.

    With protected time for basic investigation, I dedicate my entire laboratory to the study of pediatric and young adult fusion oncogene-associated sarcomas. In efforts always angling toward improved targeted therapies, we use mouse genetic models of sarcomagenesis to dissect pathways of importance to initiation and progression of tumors. This work utilizes conditional activation of translocation-associated fusion oncogenes as well as manipulation of additional modifying genes directed toward improved understanding of the conditions that promote or inhibit sarcomagenesis. This work has led to generous experience with comparative genomics and epigenomics.

    The simple genetic changes that drive translocation-associated sarcomas make a strong argument for cancer being defined as a transcriptional state for cells, rather than a state of accumulated mutations or genetic losses and gains. The study of the epigenetic determinants of this transcriptional state in cells that harbor very few genetic code alterations has already revealed important knowledge that pertains to more complex genome cancer types as well as to transcriptional biology more generally.

    I also believe firmly in the synergy possible in collaborative team science. Such efforts are required for progress toward improved treatments for rare malignancies that can never be studied with optimal efficacy in a silo. With such collaborative work as direct goal, I have participated in and assembled teams to work on pediatric sarcomas both within my institution and internationally.

    Specialties

    Patient Rating

    4.9 /5
    ( out of 124 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 24, 2024
    HUNTSMAN CANCER CENTER

    Excellent provider. Very caring and accessible to patients, willing to take the time to make sure they are comfortable with their surgeries and focused on their longterm quality of life.

    September 12, 2024
    HUNTSMAN CANCER CENTER

    I was impressed with the knowledge that he had of my condition and how he would proceed with treatment he was very personable and friendly. explained everything in a way that was easy to understand and made me feel comfortable with the treatment that I will be receiving I am looking forward to him being the Dr chosen to take care of me.

    July 15, 2024
    PRIMARY CHILDREN'S MEDICAL CENTER

    Dr Jones is amazing. We felt extremely reassured by his competency and knowledge. He was also so caring about our son, making sure that we had every resource to resolve the issue. Impeccable bedside manner. You can tell he genuinely cares for his patients and it shows in his work and each interaction.

    June 11, 2024
    HUNTSMAN CANCER CENTER

    He is caring and very professional

    June 11, 2024
    HUNTSMAN CANCER CENTER

    Excellent physician and surgeon

    May 16, 2024
    HUNTSMAN CANCER CENTER

    Dr Jones has been very kind and knowledgeable in assisting me with PVNS surgery and all its other ugly side effects

    April 16, 2024
    HUNTSMAN CANCER CENTER

    Meeting Dr. Jones and having him review my case and discuss various options and courses of action was a pleasure. His experience and wisdom come through quickly when conversing with him. I was very impressed w/Dr. Jones and his staff as a result of my office visit. I look forward to my surgery next Wednesday.

    April 10, 2024
    HUNTSMAN CANCER CENTER

    I am very greatful for the quality of care I received from Dr. Jones. He was very intelligent, very gentle, soft-spoken, precise. My entire care team at the Sarcoma Center are outstanding medical professionals and wonderful human beings.

    April 09, 2024
    HUNTSMAN CANCER CENTER

    Dr. Jones is a phenomenal surgeon. I contribute the successful findings & treatment to him. He explains everything so thoroughly & truly cares about his patients. I would recommend Dr. Jones to anyone in need of his services.

    See More Patient Comments

  • Kevin B. Jones, MD

    Leader, Huntsman Cancer Institute Sarcoma Disease Center

    Division Chief, Sarcoma, Department of Orthopaedics

    Professor, Department of Orthopaedics and

    Adjunct Professor of Oncological Sciences

    As an orthopaedic surgeon specialized in the care of pediatric and adult patients with sarcoma, I see first-hand the limitations and frank failures of the currently available treatment options. Not only do we fail to cure far too many young patients with sarcomas, but the long-term effects of our treatments create other major challenges to the health of the survivors in the long term.

    With protected time for basic investigation, I dedicate my entire laboratory to the study of pediatric and young adult fusion oncogene-associated sarcomas. In efforts always angling toward improved targeted therapies, we use mouse genetic models of sarcomagenesis to dissect pathways of importance to initiation and progression of tumors. This work utilizes conditional activation of translocation-associated fusion oncogenes as well as manipulation of additional modifying genes directed toward improved understanding of the conditions that promote or inhibit sarcomagenesis. This work has led to generous experience with comparative genomics and epigenomics.

    The simple genetic changes that drive translocation-associated sarcomas make a strong argument for cancer being defined as a transcriptional state for cells, rather than a state of accumulated mutations or genetic losses and gains. The study of the epigenetic determinants of this transcriptional state in cells that harbor very few genetic code alterations has already revealed important knowledge that pertains to more complex genome cancer types as well as to transcriptional biology more generally.

    I also believe firmly in the synergy possible in collaborative team science. Such efforts are required for progress toward improved treatments for rare malignancies that can never be studied with optimal efficacy in a silo. With such collaborative work as direct goal, I have participated in and assembled teams to work on pediatric sarcomas both within my institution and internationally.

    Board Certification and Academic Information

    Academic Departments Orthopaedics -Primary
    Oncological Sciences -Adjunct

    Education history

    Other Training Mentored Scientific Training-Mouse Genetic Modeling of Sarcoma - Mario Capecchi Laboratory, ÈËÆÞÖгöÊÓƵ of Utah
    Musculoskeletal Oncology - Mount Sinai Hospital Fellow
    Residency Orthopaedic Surgery - ÈËÆÞÖгöÊÓƵ of Iowa Hospitals and Clinics Resident
    Medicine - Johns Hopkins ÈËÆÞÖгöÊÓƵ M.D.
    Undergraduate English and American Literature and Language - Harvard ÈËÆÞÖгöÊÓƵ A.B.

    Selected Publications

    Journal Article

    1. Fatema K, Wang Y, Pavek A, Larson Z, Nartker C, Plyler S, Jeppesen A, Mehling B, Capecchi MR, Jones KB, Barrott JJ (2024). Arid1a Loss Enhances Disease Progression in a Murine Model of Osteosarcoma. Cancers (Basel), 16(15). ()
    2. Floros KV, FairÈËÆÞÖгöÊÓƵ CK Jr, Li J, Zhang K, Roberts JL, Kurupi R, Hu B, Kraskauskiene V, Hosseini N, Shen S, Inge MM, Smith-Fry K, Li L, Sotiriou A, Dalton KM, Jose A, Abdelfadiel EI, Xing Y, Hill RD, Slaughter JM, Shende M, Lorenz MR, Hinojosa MR, Belvin BR, Lai Z, Boikos SA, Stamatouli AM, Lewis JP, Manjili MH, Valerie K, Li R, Banito A, Poklepovic A, Koblinski JE, Siggers T, Dozmorov MG, Jones KB, Radhakrishnan SK, Faber AC (2024). Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma. Res Sq. ()
    3. Westlake B, Brown J, Hart J, Skiby C, Jones K, Groundland J (2024). Exploring the Diagnostic Dilemma of Indeterminate Pulmonary Nodules in Patients with Primary Sarcoma of Bone. Sarcoma, 2024, 9926675. ()
    4. Amann ES, Ose J, Hathaway CA, Oswald LB, Hardikar S, Himbert C, Chellam V, Lin T, Daniels B, Kirchhoff AC, Gigic B, Grossman D, Tward J, Varghese TK Jr, Shibata D, Figueiredo JC, Toriola AT, Beck A, Scaife C, Barnes CA, Matsen C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Grady WM, Schneider M, Dinkel A, Islam JY, Gonzalez BD, Otto AK, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2024). Risk factors and health behaviors associated with loneliness among cancer survivors during the COVID-19 pandemic. J Behav Med, 47(3), 405-421. ()
    5. Prakasam G, Mishra A, Christie A, Miyata J, Carrillo D, Tcheuyap VT, Ye H, Do QN, Wang Y, Reig Torras O, Butti R, Zhong H, Gagan J, Jones KB, Carroll TJ, Modrusan Z, Durinck S, Requena-Komuro MC, Williams NS, Pedrosa I, Wang T, Rakheja D, Kapur P, Brugarolas J (2024). Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis. J Clin Invest. ()
    6. Pozner A, Li L, Verma SP, Wang S, Barrott JJ, Nelson ML, Yu JSE, Negri GL, Colborne S, Hughes CS, Zhu JF, Lambert SL, Carroll LS, Smith-Fry K, Stewart MG, Kannan S, Jensen B, John CM, Sikdar S, Liu H, Dang NH, Bourdage J, Li J, Vahrenkamp JM, Mortenson KL, Groundland JS, Wustrack R, Senger DL, Zemp FJ, Mahoney DJ, Gertz J, Zhang X, Lazar AJ, Hirst M, Morin GB, Nielsen TO, Shen PS, Jones KB (2024). ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97. Nat Commun, 15(1), 1165. ()
    7. Brown JM, Patel R, Smith-Fry K, Ward M, Oliver T, Jones KB (2024). Genetically engineered mouse model of pleomorphic liposarcoma: Immunophenotyping and histologic characterization. Neoplasia, 48, 100956. ()
    8. Ozenberger BB, Li L, Wilson ER, Lazar AJ, Barrott JJ, Jones KB (2023). EWSR1::ATF1 Orchestrates the Clear Cell Sarcoma Transcriptome in Human Tumors and a Mouse Genetic Model. Cancers (Basel), 15(24). ()
    9. Wang XQ, Brown JM, Lorimer S, Jones KB, Groundland JS (2023). Thermal necrosis in orthopedic bone tumors: experimental research. Ann Med Surg (Lond), 85(9), 4372-4377. ()
    10. Bove JV, Webster F, Amary F, Baumhoer D, Bloem JLH, Bridge J, Cates JM, de Alava E, Dei Tos AP, Jones KB, Mahar A, Nielsen GP, Righi A, Wagner AJ, Yoshida A, Fletcher CD (2022). Datasets for the reporting of primary tumour in bone: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 82(4), 531-540. ()
    11. Brown JM, Rakoczy K, Tokson JH, Jones KB, Groundland JS (2022). Ewing sarcoma of the pelvis: Clinical features and overall survival(). Cancer Treat Res Commun, 33, 100634. ()
    12. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2022). Factors associated with changes in exercise behaviors during the COVID-19 pandemic. Cancer Causes Control, 33(7), 939-950. ()
    13. Pires G, Moss WD, Luo J, Zhang R, Jones KB, Kwok AC, Agarwal JP (2022). Free Vascularized Fibula Salvage of Failed CPH in Pediatric Sarcoma Patients. Sarcoma, 2022, 6240293. ()
    14. Brashears CB, Prudner BC, Rathore R, Caldwell KE, Dehner CA, Buchanan JL, Lange SES, Poulin N, Sehn JK, Roszik J, Spitzer D, Jones KB, OKeefe RJ, Nielsen TO, Taylor EB, Held JM, Hawkins W, Van Tine BA (2022). Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT3102. Clin Cancer Res, 28, 3573-3589. ()
    15. Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM (2022). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. J Rural ÈËÆÞÖгöÊÓƵ, 38(4), 886-899. ()
    16. Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, DeRose YS, Zhao L, Cortes-Sanchez E, Yang CH, Toner J, Wang G, Qiao Y, Huang X, Greenland JA, Vahrenkamp JM, Lum DH, Factor RE, Nelson EW, Matsen CB, Poretta JM, Rosenthal R, Beck AC, Buys SS, Vaklavas C, Ward JH, Jensen RL, Jones KB, Li Z, Oesterreich S, Dobrolecki LE, Pathi SS, Woo XY, Berrett KC, Wadsworth ME, Chuang JH, Lewis MT, Marth GT, Gertz J, Varley KE, Welm BE, Welm AL (2022). A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer, 3(2), 232-250. ()
    17. Brown JM, Rakoczy K, Hart J, Jones KB, Groundland JS (2022). Presenting features and overall survival of chondrosarcoma of the pelvis. Cancer Treat Res Commun, 30, 100510. ()
    18. Groundland J, Brown JM, Monument M, Bernthal N, Jones KB, Randall RL (2021). What Are the Long-term Surgical Outcomes of Compressive Endoprosthetic Osseointegration of the Femur with a Minimum 10-year Follow-up Period? Clin Orthop Relat Res, 480, 539-548. ()
    19. Kraus RD, Weil CR, Wells S, Tward JD, Groundland JS, Jones KB, Cannon DM (2021). Radiation Therapy in Conjunction With Surgical Stabilization of Impending or Pathologic Fractures Secondary to Metastasis: Is There a Difference Between Single and Multifraction Regimens? Adv Radiat Oncol, 7(2), 100795. ()
    20. Kim SK, Nguyen C, Jones KB, Tashjian RZ (2021). A genome-wide association study for shoulder impingement and rotator cuff disease. J Shoulder Elbow Surg, 30(9), 2134-2145. ()
    21. Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bove JVMG, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque Lpez MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A (2021). Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer, 127(16), 2934-2942. ()
    22. Panza E, Ozenberger BB, Straessler KM, Barrott JJ, Li L, Wang Y, Xie M, Boulet A, Titen SW, Mason CC, Lazar AJ, Ding L, Capecchi MR, Jones KB (2020). The clear cell sarcoma functional genomic landscape. J Clin Invest, 131(15). ()
    23. Kannan S, Lock I, Ozenberger BB, Jones KB (2021). Genetic drivers and cells of origin in sarcomagenesis. J Pathol, 254(4), 474-493. ()
    24. Groundland J, Brown J, Jones K, Randall RL (2021). Is osseous reattachment of the greater trochanter necessary compared to soft-tissue-only abductor repair in proximal femoral megaprosthesis reconstruction? J Surg Oncol, 124(1), 115-123. ()
    25. Li J, Mulvihill TS, Li L, Barrott JJ, Nelson ML, Wagner L, Lock IC, Pozner A, Lambert SL, Ozenberger BB, Ward MB, Grossmann AH, Liu T, Banito A, Cairns BR, Jones KB (2021). A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction. Cancer Discov, 11(10), 2620-2637. ()
    26. Tashjian RZ, Kim SK, Roche MD, Jones KB, Teerlink CC (2020). Genetic variants associated with rotator cuff tearing utilizing multiple population-based genetic resources. J Shoulder Elbow Surg, 30(3), 520-531. ()
    27. Schneider P, Giglio V, Ghanem D, Wilson D, Turcotte R, Isler M, Mottard S, Miller B, Hayden J, Doung YC, Gundle K, Randall RL, Jones K, Vlez R, Ghert M (2021). Willingness of patients with sarcoma to participate in cancer surveillance research: a cross-sectional patient survey. BMJ Open, 11(2), e042742. ()
    28. Kim J, Light N, Subasri V, Young EL, Wegman-Ostrosky T, Barkauskas DA, Hall D, Lupo PJ, Patidar R, Maese LD, Jones K, Wang M, Tavtigian SV, Wu D, Shlien A, Telfer F, Goldenberg A, Skapek SX, Wei JS, Wen X, Catchpoole D, Hawkins DS, Schiffman JD, Khan J, Malkin D, Stewart DR (2021). Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma. JCO Precis Oncol, 5. ()
    29. Nacev BA, Jones KB, Intlekofer AM, Yu JSE, Allis CD, Tap WD, Ladanyi M, Nielsen TO (2020). The epigenomics of sarcoma. Nat Rev Cancer, 20(10), 608-623. ()
    30. Tashjian RZ, Lock I, Granger EK, Wang Y, Lee Y, Chalmers PN, Jones KB (2020). Gene Expression in Torn Rotator Cuff Tendons Determined by RNA Sequencing. Orthop J Sports Med, 8(6), 2325967120927480. ()
    31. Blank AT, Larson BM, Shaw S, Wakefield CJ, King T, Jones KB, Randall RL (2020). National Comprehensive Cancer Network guidelines compliance of a sarcoma service: A retrospective review. World J Clin Oncol, 11(6), 389-396. ()
    32. Lambert SL, Jones KB (2020). SKP2 My Lou, My Darling. Cancer Res, 80(12), 2437-2438. ()
    33. Kirkham M, Kalivas A, Fatema K, Luelling S, Dubansky BH, Dubansky B, Jones KB, Barrott JJ (2020). Underlying Ossification Phenotype in a Murine Model of Metastatic Synovial Sarcoma. Int J Mol Sci, 21(7). ()
    34. Miller DT, Corts-Ciriano I, Pillay N, Hirbe AC, Snuderl M, Bui MM, Piculell K, Al-Ibraheemi A, Dickson BC, Hart J, Jones K, Jordan JT, Kim RH, Lindsay D, Nishida Y, Ullrich NJ, Wang X, Park PJ, Flanagan AM (2020). Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs. Genes (Basel), 11(4). ()
    35. Blank AT, Shaw S, Wakefield CJ, Zhang Y, Liu WJ, Jones KB, Randall RL (2019). What factors influence patient experience in orthopedic oncology office visits? World J Clin Oncol, 11(3), 136-142. ()
    36. Abbott D, OBrien S, Farnham JM, Young EL, Yap J, Jones K, Lessnick SL, Randall RL, Schiffman JD, Cannon-Albright LA (2019). Increased risk for other cancers in individuals with Ewing sarcoma and their relatives. Cancer Med, 8(18), 7924-7930. ()
    37. Jones KB (2019). Dendritic Cells Drive Osteosarcomagenesis through Newly Identified Oncogene and Tumor Suppressor. Cancer Discov, 9(11), 1484-1486. ()
    38. Goodwin ML, Gundavda MK, Reddy R, Deogaonkar K, Lala M, Baliarsing A, Sciubba DM, Jones KB, Agarwal M (2019). Extracorporeal radiation and reimplantation: a safe and viable option for reconstruction after sacral tumor resection? Ann Transl Med, 7(10), 229. ()
    39. Barrott JJ, Illum BE, Jin H, Hedberg ML, Wang Y, Grossmann A, Haldar M, Capecchi MR, Jones KB (2018). Paracrine osteoprotegerin and beta-catenin stabilization support synovial sarcomagenesis in periosteal cells. J Clin Invest, 128(1), 207-218. ()
    40. Kwok AC, Tatro E, Jones KB, Agarwal JP (2017). Pedicled Retrograde Fibula Flap for Ankle Reconstruction after Oncologic Resection of the Distal Fibula. Plast Reconstr Surg Glob Open, 5(2), e1232. ()
    41. Barrott JJ, Kafchinski LA, Jin H, Potter JW, Kannan SD, Kennedy R, Mosbruger T, Wang WL, Tsai JW, Araujo DM, Liu T, Capecchi MR, Lazar AJ, Jones KB (2016). Modeling synovial sarcoma metastasis in the mouse: PI3'-lipid signaling and inflammation. J Exp Med, 213(13), 2989-3005. ()
    42. Hansen SA, Hart ML, Busi S, Parker T, Goerndt A, Jones K, Amos-Landgraf JM, Bryda EC (2016). Fischer-344 Tp53-knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis. Dis Model Mech, 9(10), 1139-1146. ()
    43. Jones KB, Barrott JJ, Xie M, Haldar M, Jin H, Zhu JF, Monument MJ, Mosbruger TL, Langer EM, Randall RL, Wilson RK, Cairns BR, Ding L, Capecchi MR (2016). The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis. Oncogene, 35(38), 5021-32. ()
    44. Barrott JJ, Illum BE, Jin H, Zhu JF, Mosbruger T, Monument MJ, Smith-Fry K, Cable MG, Wang Y, Grossmann AH, Capecchi MR, Jones KB (2015). beta-catenin stabilization enhances SS18-SSX2-driven synovial sarcomagenesis and blocks the mesenchymal to epithelial transition. Oncotarget, 6(26), 22758-66. ()
    45. Quist T, Jin H, Zhu JF, Smith-Fry K, Capecchi MR, Jones KB (2015). The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse. Oncogene, 34(32), 4278-84. ()
    46. de Andrea CE, Zhu JF, Jin H, Bovee JV, Jones KB (2015). Cell cycle deregulation and mosaic loss of Ext1 drive peripheral chondrosarcomagenesis in the mouse and reveal an intrinsic cilia deficiency. J Pathol, 236(2), 210-8. ()
    47. Monument MJ, Bernthal NM, Bowles AJ, Jones KB, Randall RL (2015). What are the 5-year survivorship outcomes of compressive endoprosthetic osseointegration fixation of the femur? Clin Orthop Relat Res, 473(3), 883-90. ()
    48. Goodwin ML, Jin H, Straessler K, Smith-Fry K, Zhu JF, Monument MJ, Grossmann A, Randall RL, Capecchi MR, Jones KB (2014). Modeling alveolar soft part sarcomagenesis in the mouse: a role for lactate in the tumor microenvironment. Cancer Cell, 26(6), 851-862. ()
    49. Jones KB, Su L, Jin H, Lenz C, Randall RL, Underhill TM, Nielsen TO, Sharma S, Capecchi MR (2013). SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. Oncogene, 32(18), 2365-71, 2375.e1-5. ()
    50. Jones KB, Datar M, Ravichandran S, Jin H, Jurrus E, Whitaker R, Capecchi MR (2013). Toward an understanding of the short bone phenotype associated with multiple osteochondromas. J Orthop Res, 31(4), 651-7. ()
    51. Straessler KM, Jones KB, Hu H, Jin H, van de Rijn M, Capecchi MR (2013). Modeling clear cell sarcomagenesis in the mouse: cell of origin differentiation state impacts tumor characteristics. Cancer Cell, 23(2), 215-27. ()
    52. Jones KB, Ferguson PC, Lam B, Biau DJ, Hopyan S, Deheshi B, Griffin AM, White LM, Wunder JS (2012). Effects of neoadjuvant chemotherapy on image-directed planning of surgical resection for distal femoral osteosarcoma. J Bone Joint Surg Am, 94(15), 1399-405. ()
    53. Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, Volinia S, Stein GS, Croce CM, Lian JB, Aqeilan RI (2012). miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res, 72(7), 1865-77. ()
    54. Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, Volinia S, Stein GS, Croce CM, Lian JB, Ageilan RI (04/01/2012). miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res, 72(7), 1865-77.
    55. Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S, Poulin N, Yi L, Rossi FM, Kast J, Capecchi MR, Underhill TM, Nielsen TO (2012). Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell, 21(3), 333-47. ()
    56. Jones KB, Schiffman JD, Kohlmann W, Randall RL, Lessnick SL, Cannon-Albright LA (2011). Complex genotype sarcomas display familial inheritance independent of known cancer predisposition syndromes. Cancer Epidemiol Biomarkers Prev, 20(5), 751-7. ()
    57. Israelsen RB, Illum BE, Crabtree S, Randall RL, Jones KB (2011). Extremity sarcoma surgery in younger ÈËÆÞÖгöÊÓƵren: ten years of patients ten years and under. Iowa Orthop J, 31, 145-53. ()
    58. Jones KB, Piombo V, Searby C, Kurriger G, Yang B, Grabellus F, Roughley PJ, Morcuende JA, Buckwalter JA, Capecchi MR, Vortkamp A, Sheffield VC (2010). A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc Natl Acad Sci U S A, 107(5), 2054-9. ()
    59. Jones KB (2007). Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long bones [Skeletal Lesion Interobserver Correlation among Expert Diagnosticians (SLICED) Study Group ]. J Bone Joint Surg Am, 89(10), 2113-2123.
    60. Jones KB, Buckwalter JA, Frassica FJ, McCarthy EF (2005). Intracortical chondroma: a report of two cases. Skeletal Radiol, 35(5), 298-301. ()

    Review

    1. Stacchiotti S, Maria Frezza A, Demetri GD, Blay JY, Bajpai J, Baldi GG, Baldini EH, Benjamin RS, Bonvalot S, Bove JVMG, Callegaro D, Casali PG, DAngelo SP, Davis EJ, Dei Tos AP, Demicco EG, Desai J, Dileo P, Eriksson M, Gelderblom H, George S, Gladdy RA, Gounder MM, Gupta AA, Haas R, Hayes A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Maestro R, Martin Broto J, Maki RG, Miah AB, Palmerini E, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Strauss SJ, Tap WD, Thomas DM, Trama A, Trent JC, van der Graaf WTA, van Houdt WJ, von Mehren M, Wilky BA, Fletcher CDM, Gronchi A, Miceli R, Wagner AJ (2022). Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. [Review]. Cancer Treat Rev, 110, 102455. ()
    2. Burns J, Brown JM, Jones KB, Huang PH (2022). The Cancer Genome Atlas: Impact and Future Directions in Sarcoma. [Review]. Surg Oncol Clin N Am, 31(3), 559-568. ()

    Case Report

    1. Abbasi AM, Hosein RC, Willis RN Jr, Lelkes VM, Jones KB, Agarwal JP (2020). Modified Rotationplasty as a Composite Free Flap for Femur and Thigh Reconstruction. World J Plast Surg, 10(2), 115-119. ()
    2. Serpico R, Brown J, Blank A, Jones K, Randall RL, Groundland J (2021). Metastasis of Osteosarcoma to the Abdomen: A Report of Two Cases and a Review of the Literature. Case Rep Oncol, 14(1), 647-658. ()
    3. Blank AT, Wakefield C, Khalighi M, Jones KB, Randall RL (2020). Epithelioid Osteoblastoma of the Proximal Femur in a 19-Year-Old Female: A Case Report and Review of Literature. J Orthop Case Rep, 9(5), 74-77. ()

    Other

    1. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2021). Impact of the COVID-19 pandemic on exercise habits among cancer patients. United States. ()

  • News & Podcasts

    Huntsman Cancer Institute News